The impaired APP cleavage caused by the mutations results in the increased production of amyloid beta (Aβ)1–42 peptides and failure in the Aβ clearance, thus providing an explanation for the Aβ accumulation in the brain of early-onset AD patients [1]. The gene discussed is APP; the disease is Alzheimer disease.